| Published Application/Species/Sample/Dilution | Reference |
|---|
- immunohistochemistry; human; fig 1
| Hirayama M, Tomita Y, Yuno A, Tsukamoto H, Senju S, Imamura Y, et al. An oncofetal antigen, IMP-3-derived long peptides induce immune responses of both helper T cells and CTLs. Oncoimmunology. 2016;5:e1123368 pubmed publisher |
- immunohistochemistry - paraffin section; human; 1:100; loading ...; fig 1a
| Shooshtarizadeh T, Nazeri A, Zare Mirzaie A, Movahedinia S. Expression of insulin-like growth factor II mRNA binding protein 3 (IMP3) in enchondroma and chondrosarcoma. Pathol Res Pract. 2016;212:335-9 pubmed publisher |
- immunohistochemistry - paraffin section; human; 1:100; tbl 4
| Helbig D, Ihle M, Pütz K, Tantcheva Poor I, Mauch C, Büttner R, et al. Oncogene and therapeutic target analyses in atypical fibroxanthomas and pleomorphic dermal sarcomas. Oncotarget. 2016;7:21763-74 pubmed publisher |
- western blot; human; fig 3d
| Zhang X, Jung I, Hwang Y. EGF enhances low-invasive cancer cell invasion by promoting IMP-3 expression. Tumour Biol. 2016;37:2555-63 pubmed publisher |
- western blot; human; 1:1000; loading ...; fig 1b
| Pasiliao C, Chang C, Sutherland B, Valdez S, Schaeffer D, Yapp D, et al. The involvement of insulin-like growth factor 2 binding protein 3 (IMP3) in pancreatic cancer cell migration, invasion, and adhesion. BMC Cancer. 2015;15:266 pubmed publisher |
| Del Gobbo A, Vaira V, Ferrari L, Patriarca C, Di Cristofori A, Ricca D, et al. The oncofetal protein IMP3: a novel grading tool and predictor of poor clinical outcome in human gliomas. Biomed Res Int. 2015;2015:413897 pubmed publisher |
| Soddu S, Di Felice E, Cabras S, Castellanos M, Atzori L, Faa G, et al. IMP-3 expression in keratoacanthomas and squamous cell carcinomas of the skin: an immunohistochemical study. Eur J Histochem. 2013;57:e6 pubmed publisher |
